相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Tim A. Labeur et al.
LIVER INTERNATIONAL (2020)
A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.
Masatoshi Kudo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
Masatoshi Kudo
CANCERS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017
Longfei Lin et al.
LIVER CANCER (2020)
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee et al.
LANCET ONCOLOGY (2020)
N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling
Junjie Xu et al.
MOLECULAR CANCER (2020)
Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma
Jens Ricke et al.
JHEP REPORTS (2020)
High-signal-intensity MR Image in the Hepatobiliary Phase Predicts Long-term Survival in Patients With Hepatocellular Carcinoma
SHUN-ICHI ARIIZUMI et al.
ANTICANCER RESEARCH (2019)
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta et al.
CANCER DISCOVERY (2019)
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
Jens Ricke et al.
JOURNAL OF HEPATOLOGY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC
Roser Pinyol et al.
CLINICAL CANCER RESEARCH (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma
Mengxi Huang et al.
CANCER LETTERS (2017)
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
Hsiao-Hui Lin et al.
CANCER LETTERS (2016)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics
Azusa Kitao et al.
RADIOLOGY (2015)
Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging and Alpha-Fetoprotein Predict Prognosis of Early-Stage Hepatocellular Carcinoma
Taro Yamashita et al.
HEPATOLOGY (2014)
OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma
Akihisa Ueno et al.
JOURNAL OF HEPATOLOGY (2014)
Hepatocellular Carcinoma: Signal Intensity at Gadoxetic Acid-enhanced MR Imaging-Correlation with Molecular Transporters and Histopathologic Features
Azusa Kitao et al.
RADIOLOGY (2010)
Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: Is it possible to shorten the examination time?
Utaroh Motosugi et al.
EUROPEAN RADIOLOGY (2009)
Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma
Masato Narita et al.
JOURNAL OF GASTROENTEROLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
分享论文
